Fermenta Biotech Limited will host a one-to-one physical meeting with investors in Mumbai on August 21, 2026. The company issued the intimation on August 17, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The interaction is scheduled to take place in a physical format at a location in Mumbai. Fermenta Biotech stated that company officials will participate in the meeting to discuss matters of interest to investors.

Information Disclosure

The company clarified that all relevant press releases and investor presentations proposed for discussion are already available on its website and on the stock exchanges where its shares are listed. Fermenta Biotech explicitly noted that no unpublished price-sensitive information (UPSI) is intended to be discussed during the interaction.

Varadvinayak Khambete, Company Secretary and Head – Legal, signed the disclosure. The company added that changes to the schedule may occur due to exigencies on the part of the company or investors.

Fermenta Biotech reported a consolidated net profit of ₹95.3 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 56% decline year-on-year. However, the company’s standalone performance showed resilience, with net profit rising 7% YoY to ₹149.9 crore. The significant drop in consolidated profitability was primarily attributed to a 40% fall in Vitamin D3 – Animal Nutrition realisations and the absence of ₹2.7 crore in non-recurring insurance income that had boosted the prior year’s base. Consolidated revenue, including real estate value unlocking, stood at ₹126.2 crore, down 13% YoY but flat quarter-on-quarter.

The standalone entity recorded total income from operations of ₹116.7 crore, down 9% YoY from ₹127.9 crore in Q1FY26. Despite the revenue contraction, standalone profit before tax remained robust at ₹201.5 crore, compared to ₹227.2 crore in the corresponding period last year. This contrasts with the consolidated profit before tax, which fell to ₹146.9 crore from ₹280.9 crore YoY. Diluted earnings per share on a consolidated basis were ₹3.34, while basic EPS stood at ₹3.40.

Segment Performance

The human nutrition segment remained the largest contributor, accounting for 61% of consolidated revenue with sales of ₹76.5 crore. While human nutrition volumes rose 18% QoQ, revenue in this segment fell 10% YoY to ₹76.5 crore. In contrast, the animal nutrition segment faced headwinds, with revenue dropping 41% YoY to ₹12.6 crore due to a 40% decline in average realisations. Volumes in animal nutrition were down 52% QoQ and 20% YoY.

Other business lines showed growth. Other APIs and Intermediates revenue grew 18% YoY to ₹11.6 crore, while Green Chemistry Solutions / Enzymes rose 15% YoY to ₹2.3 crore. The 'Others' line within nutrition grew 28% YoY to ₹11.0 crore. Environmental Solutions revenue surged 619% QoQ to ₹6.0 crore, though it declined 8% YoY.

Geographical Shifts

India emerged as a stronger market, contributing 47% of consolidated revenue (excluding real estate) in Q1FY27, up from 35% a year earlier and 38% in the preceding quarter. Europe’s share declined to 23% from 33% YoY, while North America accounted for 10%. This shift reflects growing domestic demand and successful customer acquisitions in smaller business lines.

Cost Structure Dynamics

Raw material costs improved to 35% of revenue in Q1FY27, against 37% in FY26 and 38% in FY25, reflecting an improved sourcing mix. However, employee costs rose to 19% of revenue, compared to 16% in FY26, when capacity expansion added heads ahead of the Dahej scale-up. Manufacturing expenses remained stable at 12%, consistent with FY26 levels but lower than the 15% recorded in FY25. Finance costs held steady at 2% of revenue, indicating continued deleveraging efforts.

What the Numbers Show

The divergence between standalone and consolidated results is notable. While the standalone entity managed to increase net profit by 7% YoY despite a 9% revenue drop, the consolidated bottom line contracted sharply by 56%. This suggests that inter-company eliminations or specific subsidiary losses (likely driven by the volatile animal nutrition segment) are weighing heavily on the group numbers. The rise in India’s revenue share to 47% signals a strategic pivot towards domestic markets, reducing reliance on volatile international segments like Europe, which saw its share drop by 10 percentage points YoY.

Operational Updates

Prashant Nagre, Managing Director, stated that the quarter was about “building rather than harvesting,” emphasizing growth in emerging segments like Green Chemistry and Other APIs. Post-quarter, Fermenta received FSSAI approval on July 6, 2026, for VITADEE Green®, its plant-source Vitamin D3, for use in health supplements and food fortification. This approval opens access to India’s large vegetarian consumer base. Additionally, the company ranked 7th nationwide in the Top 50 category of India’s Great Mid-size Workplaces™ 2026.